REFR vs KOSS vs VUZI vs MVIS

For growth investors, Vuzix Corporation (VUZI) is the stronger pick with 1090% revenue growth year-over-year, versus -74.

3% for MicroVision, Inc. (MVIS). Analysts rate Vuzix Corporation (VUZI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Research Frontiers Incorporated (REFR) delivered a total return of -66.

9%, compared to -95. 6% for MicroVision, Inc. (MVIS). Over 10 years, the gap is even starker: KOSS returned +91. 0% versus REFR's -80. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Research Frontiers Incorporated (REFR) is the lower-risk stock at 0.

86β versus Vuzix Corporation's 3. 40β — meaning VUZI is approximately 296% more volatile than REFR relative to the S&P 500. On balance sheet safety, Vuzix Corporation (VUZI) carries a lower debt/equity ratio of 4% versus 125% for Research Frontiers Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vuzix Corporation (VUZI) is pulling ahead at 1090% versus -74.

3% for MicroVision, Inc. (MVIS). On earnings-per-share growth, the picture is similar: Vuzix Corporation grew EPS 61. 1% year-over-year, compared to -55. 5% for Research Frontiers Incorporated. Over a 3-year CAGR, VUZI leads at 709. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Koss Corporation (KOSS) is the more profitable company, earning -6.

9% net margin versus -78. 6% for MicroVision, Inc. — meaning it keeps -6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KOSS leads at -13. 8% versus -57. 4% for MVIS. At the gross margin level — before operating expenses — REFR leads at 83. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, VUZI (10.

1% yield) pays a dividend. REFR, KOSS, MVIS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Research Frontiers Incorporated (REFR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

86)). MicroVision, Inc. (MVIS) carries a higher beta of 2. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REFR: -80. 2%, MVIS: -66. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: REFR is a small-cap quality compounder stock; KOSS is a small-cap quality compounder stock; VUZI is a small-cap high-growth stock; MVIS is a small-cap quality compounder stock. VUZI pays a dividend while REFR, KOSS, MVIS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.